Relapsed/Refractory Peripheral T-Cell Lymphoma
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
DS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Daiichi SankyoValemetostat Tosylate
Taiho OncologyTolinapant
Clinical Trials (2)
Total enrollment: 155 patients across 2 trials
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Start: Jun 2021Est. completion: Feb 2027155 patients
Phase 2Active Not Recruiting
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Start: Feb 2023Est. completion: Mar 2026
Phase 1Active Not Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
8m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
8m ago
Office Administrator
SystImmune
8m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
18m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
22m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
22m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space